Ilunocitinib
Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1) [1].
Product Specifications
CAS Number
[1187594-14-4]
Product Name Alternative
LY-3411067
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/ilunocitinib.html
Purity
98.24
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
N#CCC1(CN(S(=O)(C2CC2)=O)C1)N3N=CC(C4=C5C=CNC5=NC=N4)=C3
Molecular Formula
C17H17N7O2S
Molecular Weight
383.43
References & Citations
[1]James D. Rodgers, et al. Azetidine and cyclobutane derivatives as jak inhibitors. Patent. WO2009114512A1.|[2]Forster S, et al. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Vet Dermatol. 2025 Jan 6.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6455028-01 0.1 mL
CELA2B (Chymotrypsin-like Elastase Family Member 2B, Elastase-2B, CELA2B, ELA2B) (PE)
Ask
View Details 
MBS6455028-02 5x 0.1 mL
CELA2B (Chymotrypsin-like Elastase Family Member 2B, Elastase-2B, CELA2B, ELA2B) (PE)
Ask
View Details 